[go: up one dir, main page]

DK1820506T3 - Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf - Google Patents

Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1820506T3
DK1820506T3 DK06250764T DK06250764T DK1820506T3 DK 1820506 T3 DK1820506 T3 DK 1820506T3 DK 06250764 T DK06250764 T DK 06250764T DK 06250764 T DK06250764 T DK 06250764T DK 1820506 T3 DK1820506 T3 DK 1820506T3
Authority
DK
Denmark
Prior art keywords
formulation
extended release
preparation
release dipyridamole
formulations
Prior art date
Application number
DK06250764T
Other languages
English (en)
Inventor
Minutza Leibovici
Itamar Kanari
Michael Fox
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1820506T3 publication Critical patent/DK1820506T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06250764T 2006-02-09 2006-02-13 Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf DK1820506T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77225706P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
DK1820506T3 true DK1820506T3 (da) 2008-07-07

Family

ID=36384355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06250764T DK1820506T3 (da) 2006-02-09 2006-02-13 Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf

Country Status (13)

Country Link
US (1) US20070184110A1 (da)
EP (1) EP1820506B1 (da)
JP (1) JP2008534681A (da)
CN (1) CN101365453A (da)
AT (1) ATE390138T1 (da)
AU (1) AU2006337643A1 (da)
CA (1) CA2640472A1 (da)
DE (1) DE602006000819T2 (da)
DK (1) DK1820506T3 (da)
ES (1) ES2303314T3 (da)
IL (1) IL193023A0 (da)
PT (1) PT1820506E (da)
WO (1) WO2007092026A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
CN101780037B (zh) * 2010-02-03 2011-11-16 南昌大学 双嘧达莫自乳化给药系统及其制备方法
CN101919822B (zh) * 2010-07-16 2013-10-23 钟术光 综合性能改善的片剂及其制备方法
WO2012150246A1 (de) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten freigabe von wirkstoffen
DK2817000T3 (da) 2012-02-21 2021-10-11 Towa Pharmaceutical Europe S L Orale farmaceutiske sammensætninger af dabigatranetexilat
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
CN103417494B (zh) * 2013-08-13 2015-12-23 杭州高成生物营养技术有限公司 一种以酒石酸作为主要成分的微丸
KR102308973B1 (ko) * 2013-12-04 2021-10-08 베링거잉겔하임베트메디카게엠베하 개선된 피모벤단의 약제학적 조성물
CN105106225A (zh) * 2015-09-10 2015-12-02 石家庄市智同医药科技有限公司 一种复方双嘧达莫阿司匹林片剂及其制备方法
EP4247354A4 (en) * 2020-11-18 2025-02-19 Fb-Hrs, Llc COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES
CN117442628A (zh) * 2023-10-27 2024-01-26 浙江歌文达生物医药科技有限公司 一种含有缓释双嘧达莫微片的速释阿司匹林包衣胶囊及其制备方法
CN118384120B (zh) * 2024-05-09 2025-07-25 山东康美乐医药科技有限公司 一种恩格列净二甲双胍缓释片剂及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE2831164A1 (de) * 1978-07-15 1980-01-24 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
ATE50497T1 (de) 1984-07-21 1990-03-15 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
WO2001021163A2 (en) * 1999-09-21 2001-03-29 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration

Also Published As

Publication number Publication date
AU2006337643A1 (en) 2007-08-16
WO2007092026A1 (en) 2007-08-16
IL193023A0 (en) 2009-02-11
EP1820506B1 (en) 2008-03-26
PT1820506E (pt) 2008-05-23
CA2640472A1 (en) 2007-08-16
JP2008534681A (ja) 2008-08-28
HK1104791A1 (en) 2008-01-25
ES2303314T3 (es) 2008-08-01
DE602006000819T2 (de) 2009-04-09
DE602006000819D1 (de) 2008-05-08
EP1820506A1 (en) 2007-08-22
CN101365453A (zh) 2009-02-11
US20070184110A1 (en) 2007-08-09
ATE390138T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
IL193023A0 (en) Dipyridamole extended-release formulations and process for preparing same
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
WO2006076620A3 (en) Bendamustine pharmaceutical compositions for lyophilisation
IL192670A (en) Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication
FI20055568A0 (fi) Menetelmä karboksyylihappoesteriseoksien valmistamiseksi ja niiden käyttö
MX347106B (es) Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
EP2045253A4 (en) alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
PL1916994T3 (pl) Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
TN2010000135A1 (en) Galenical formulations of organic compounds
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
DE602008006243D1 (de) Pharmazeutische kombination aus aliskiren und valsartan
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
WO2007014124A3 (en) High drug load formulations and dosage forms
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
IL185723A0 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür